Anti-viral treatment during pregnancy reduces HBV transmission from mother to child

An analysis of published studies indicates that the antiviral drug tenofovir given to pregnant women in the second or third trimester can help prevent mother to child transmission of the hepatitis B virus (HBV).

Universal vaccination of newborn babies has brought down to 10-30%. In their Alimentary Pharmacology & Therapeutics analysis of data from five controlled trials, Dr. Ji Hoon Kim and his colleagues found that the risk of maternal transmission to the baby is further reduced, down to only 3% (77% reduction of transmission), when the mother receives the antiviral drug tenofovir during pregnancy.

Chronic HBV infection affects approximately 240 million people worldwide. Without treatment, it is transmitted from mother to baby in about 90% of births, often causing liver disease as the child grows up. More than 600,000 people die annually because of HBV complications.


Explore further

Antenatal screening in Europe: How to avoid mother-to-child transmission of infections

More information: M. H. Hyun et al, Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus, Alimentary Pharmacology & Therapeutics (2017). DOI: 10.1111/apt.14068
Provided by Wiley
Citation: Anti-viral treatment during pregnancy reduces HBV transmission from mother to child (2017, April 24) retrieved 19 January 2019 from https://medicalxpress.com/news/2017-04-anti-viral-treatment-pregnancy-hbv-transmission.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more